MiCareo

Executive Summary

MiCareo is a San Diego-based diagnostics company developing automated systems for high-purity isolation, imaging, and analysis of rare cells from liquid biopsies. Founded in 2018, the company's platform enables researchers and pharmaceutical companies to capture live circulating tumor cells (CTCs) and immune cells for downstream analysis, facilitating drug response monitoring and biomarker discovery. By providing a non-invasive, single-cell resolution approach, MiCareo addresses key challenges in oncology diagnostics, including tumor heterogeneity and real-time treatment assessment. The company is well-positioned in the growing liquid biopsy market, with potential to improve clinical decision-making and accelerate precision medicine.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Funding Round60% success
• Q4 2026Strategic Partnership with Pharma for CTC-based Drug Monitoring50% success
• Q2 2027Launch of Next-Generation Automated Isolation Platform40% success